Skip to main content

Targos Molecular Pathology, Ultivue Partner to Provide Multiplex Assays

NEW YORK – Clinical biomarker services firm Targos Molecular Pathology said today that it has formed a partnership with Cambridge, Massachusetts-based Ultivue to provide standardized multiplex phenotypic assays to pharmaceutical companies for the characterization of samples selected for clinical research programs.

Ultivue's UltiMapper assays are used in tumor immune-profiling research strategies by the biomedical community to demonstrate the clinical utility of panels of markers.

The multiplex immunohistochemistry assays enable the precise identification of cellular phenotypes that can be associated with drug efficacy and further used to develop a companion diagnostic assay, Targos said.

The assays enable "various levels of multiplexing and throughput, and [support] same day staining-to-data workflows," Targos CEO Thomas Henkel said in a statement, adding that their adoption represents a strategic fit with the mission of Kassel, Germany-based Targos 'to continuously improve the success of clinical trials."

Financial and other terms of the deal were not disclosed.